Renal Cell Carcinoma - Pipeline Review, H1 2016

  • ID: 3753874
  • Report
  • 811 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc.
  • Bionomics Limited
  • Eli Lilly and Company
  • Incuron, LLC
  • Merck KGaA
  • OncoMax
  • MORE
Renal Cell Carcinoma - Pipeline Review, H1 2016

Summary

‘Renal Cell Carcinoma - Pipeline Review, H1 2016’, provides an overview of the Renal Cell Carcinoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Renal Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Renal Cell Carcinoma and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Renal Cell Carcinoma
- The report reviews pipeline therapeutics for Renal Cell Carcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Renal Cell Carcinoma therapeutics and enlists all their major and minor projects
- The report assesses Renal Cell Carcinoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Renal Cell Carcinoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Renal Cell Carcinoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Renal Cell Carcinoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc.
  • Bionomics Limited
  • Eli Lilly and Company
  • Incuron, LLC
  • Merck KGaA
  • OncoMax
  • MORE
Introduction

Renal Cell Carcinoma Overview

Therapeutics Development

Renal Cell Carcinoma - Therapeutics under Development by Companies

Renal Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes

Renal Cell Carcinoma - Pipeline Products Glance

Renal Cell Carcinoma - Products under Development by Companies

Renal Cell Carcinoma - Products under Investigation by Universities/Institutes

Renal Cell Carcinoma - Companies Involved in Therapeutics Development

Renal Cell Carcinoma - Therapeutics Assessment

Drug Profiles

Renal Cell Carcinoma - Recent Pipeline Updates

Renal Cell Carcinoma - Dormant Projects

Renal Cell Carcinoma - Discontinued Products

Renal Cell Carcinoma - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Renal Cell Carcinoma, H1 2016

Number of Products under Development for Renal Cell Carcinoma - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Development by Companies, H1 2016 (Contd..2)

Number of Products under Development by Companies, H1 2016 (Contd..3)

Number of Products under Development by Companies, H1 2016 (Contd..4)

Number of Products under Development by Companies, H1 2016 (Contd..5)

Number of Products under Development by Companies, H1 2016 (Contd..6)

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Comparative Analysis by Unknown Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Development by Companies, H1 2016 (Contd..3)

Products under Development by Companies, H1 2016 (Contd..4)

Products under Development by Companies, H1 2016 (Contd..5)

Products under Development by Companies, H1 2016 (Contd..6)

Products under Development by Companies, H1 2016 (Contd..7)

Products under Development by Companies, H1 2016 (Contd..8)

Products under Development by Companies, H1 2016 (Contd..9)

Products under Investigation by Universities/Institutes, H1 2016

Renal Cell Carcinoma - Pipeline by AbbVie Inc., H1 2016

Renal Cell Carcinoma - Pipeline by Acceleron Pharma, Inc., H1 2016

Renal Cell Carcinoma - Pipeline by Advenchen Laboratories, LLC, H1 2016

Renal Cell Carcinoma - Pipeline by Altor BioScience Corporation, H1 2016

Renal Cell Carcinoma - Pipeline by Ambrx, Inc., H1 2016

Renal Cell Carcinoma - Pipeline by Amgen Inc., H1 2016

Renal Cell Carcinoma - Pipeline by Ampio Pharmaceuticals, Inc., H1 2016

Renal Cell Carcinoma - Pipeline by arGEN-X BV, H1 2016

Renal Cell Carcinoma - Pipeline by Argos Therapeutics, Inc., H1 2016

Renal Cell Carcinoma - Pipeline by Arrowhead Pharmaceuticals, Inc., H1 2016

Renal Cell Carcinoma - Pipeline by Astellas Pharma Inc., H1 2016

Renal Cell Carcinoma - Pipeline by Bayer AG, H1 2016

Renal Cell Carcinoma - Pipeline by Beta Pharma, Inc., H1 2016

Renal Cell Carcinoma - Pipeline by Bio-Cancer Treatment International Limited, H1 2016

Renal Cell Carcinoma - Pipeline by BIOCAD, H1 2016

Renal Cell Carcinoma - Pipeline by Bionomics Limited, H1 2016

Renal Cell Carcinoma - Pipeline by Bionovis SA, H1 2016

Renal Cell Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016

Renal Cell Carcinoma - Pipeline by Boston Biomedical, Inc., H1 2016

Renal Cell Carcinoma - Pipeline by Bristol-Myers Squibb Company, H1 2016

Renal Cell Carcinoma - Pipeline by Caladrius Biosciences, Inc. , H1 2016

Renal Cell Carcinoma - Pipeline by Calithera Biosciences, Inc., H1 2016

Renal Cell Carcinoma - Pipeline by Cellceutix Corporation, H1 2016

Renal Cell Carcinoma - Pipeline by Celldex Therapeutics, Inc., H1 2016

Renal Cell Carcinoma - Pipeline by Celltrion, Inc., H1 2016

Renal Cell Carcinoma - Pipeline by Cerulean Pharma, Inc., H1 2016

Renal Cell Carcinoma - Pipeline by Chipscreen Biosciences Ltd, H1 2016

Renal Cell Carcinoma - Pipeline by Cytune Pharma SAS, H1 2016

Renal Cell Carcinoma - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016

Renal Cell Carcinoma - Pipeline by EirGenix Inc., H1 2016

Renal Cell Carcinoma - Pipeline by Eisai Co., Ltd., H1 2016

Renal Cell Carcinoma - Pipeline by Eli Lilly and Company, H1 2016

Renal Cell Carcinoma - Pipeline by Exelixis, Inc., H1 2016

Renal Cell Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016

Renal Cell Carcinoma - Pipeline by Genor BioPharma Co., Ltd., H1 2016

Renal Cell Carcinoma - Pipeline by GenSpera, Inc., H1 2016

Renal Cell Carcinoma - Pipeline by GlaxoSmithKline Plc, H1 2016

Renal Cell Carcinoma - Pipeline by Horizon Pharma Plc, H1 2016

Renal Cell Carcinoma - Pipeline by Hutchison MediPharma Limited, H1 2016

Renal Cell Carcinoma - Pipeline by Immatics Biotechnologies GmbH, H1 2016

Renal Cell Carcinoma - Pipeline by Immune Design Corp., H1 2016

Renal Cell Carcinoma - Pipeline by Immunicum AB, H1 2016

Renal Cell Carcinoma - Pipeline by ImmunoGen, Inc., H1 2016

Renal Cell Carcinoma - Pipeline by Incuron, LLC, H1 2016

Renal Cell Carcinoma - Pipeline by Incyte Corporation, H1 2016

Renal Cell Carcinoma - Pipeline by KAHR medical Ltd., H1 2016

Renal Cell Carcinoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2016

Renal Cell Carcinoma - Pipeline by KineMed, Inc., H1 2016

Renal Cell Carcinoma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016

Renal Cell Carcinoma - Pipeline by Lead Discovery Center GmbH, H1 2016

Renal Cell Carcinoma - Pipeline by Mabion SA, H1 2016

Renal Cell Carcinoma - Pipeline by MacroGenics, Inc., H1 2016

Renal Cell Carcinoma - Pipeline by MediaPharma s.r.l., H1 2016

Renal Cell Carcinoma - Pipeline by MedImmune, LLC, H1 2016

Renal Cell Carcinoma - Pipeline by Medivation, Inc., H1 2016

Renal Cell Carcinoma - Pipeline by Merck & Co., Inc., H1 2016

Renal Cell Carcinoma - Pipeline by Merck KGaA, H1 2016

Renal Cell Carcinoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016

Renal Cell Carcinoma - Pipeline by Mirna Therapeutics, Inc., H1 2016

Renal Cell Carcinoma - Pipeline by Molecular Partners AG, H1 2016

Renal Cell Carcinoma - Pipeline by Mologen AG, H1 2016

Renal Cell Carcinoma - Pipeline by Monopar Therapeutics LLC, H1 2016

Renal Cell Carcinoma - Pipeline by Mycenax Biotech Inc., H1 2016

Renal Cell Carcinoma - Pipeline by Nektar Therapeutics, H1 2016

Renal Cell Carcinoma - Pipeline by NewLink Genetics Corporation, H1 2016

Renal Cell Carcinoma - Pipeline by Novartis AG, H1 2016

Renal Cell Carcinoma - Pipeline by NovaTarg Therapeutics, Inc, H1 2016

Renal Cell Carcinoma - Pipeline by Omeros Corporation, H1 2016

Renal Cell Carcinoma - Pipeline by Oncobiologics, Inc., H1 2016

Renal Cell Carcinoma - Pipeline by OncoMax, H1 2016

Renal Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016

Renal Cell Carcinoma - Pipeline by Panacea Biotec Limited, H1 2016

Renal Cell Carcinoma - Pipeline by Peloton Therapeutics, Inc., H1 2016

Renal Cell Carcinoma - Pipeline by Pfizer Inc., H1 2016

Renal Cell Carcinoma - Pipeline by Prima BioMed Ltd., H1 2016

Renal Cell Carcinoma - Pipeline by PsiOxus Therapeutics Limited, H1 2016

Renal Cell Carcinoma - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2016

Renal Cell Carcinoma - Pipeline by Seattle Genetics, Inc., H1 2016

Renal Cell Carcinoma - Pipeline by Sevion Therapeutics, Inc., H1 2016

Renal Cell Carcinoma - Pipeline by Sillajen Biotherapeutics, H1 2016

Renal Cell Carcinoma - Pipeline by Sorrento Therapeutics, Inc., H1 2016

Renal Cell Carcinoma - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016

Renal Cell Carcinoma - Pipeline by Syndax Pharmaceuticals, Inc., H1 2016

Renal Cell Carcinoma - Pipeline by Taiwan Liposome Company, Ltd., H1 2016

Renal Cell Carcinoma - Pipeline by TC BioPharm Limited, H1 2016

Renal Cell Carcinoma - Pipeline by Theravectys SA, H1 2016

Renal Cell Carcinoma - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016

Renal Cell Carcinoma - Pipeline by Tocagen Inc., H1 2016

Renal Cell Carcinoma - Pipeline by TRACON Pharmaceuticals, Inc., H1 2016

Renal Cell Carcinoma - Pipeline by TVAX Biomedical, Inc., H1 2016

Renal Cell Carcinoma - Pipeline by Tyrogenex, Inc., H1 2016

Renal Cell Carcinoma - Pipeline by Vascular Biogenics Ltd., H1 2016

Renal Cell Carcinoma - Pipeline by ViiV Healthcare Limited, H1 2016

Renal Cell Carcinoma - Pipeline by X4 Pharmaceuticals, Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Renal Cell Carcinoma Therapeutics - Recent Pipeline Updates, H1 2016

Renal Cell Carcinoma - Dormant Projects, H1 2016

Renal Cell Carcinoma - Dormant Projects (Contd..1), H1 2016

Renal Cell Carcinoma - Dormant Projects (Contd..2), H1 2016

Renal Cell Carcinoma - Dormant Projects (Contd..3), H1 2016

Renal Cell Carcinoma - Dormant Projects (Contd..4), H1 2016

Renal Cell Carcinoma - Dormant Projects (Contd..5), H1 2016

Renal Cell Carcinoma - Dormant Projects (Contd..6), H1 2016

Renal Cell Carcinoma - Dormant Projects (Contd..7), H1 2016

Renal Cell Carcinoma - Dormant Projects (Contd..8), H1 2016

Renal Cell Carcinoma - Dormant Projects (Contd..9), H1 2016

Renal Cell Carcinoma - Dormant Projects (Contd..10), H1 2016

Renal Cell Carcinoma - Dormant Projects (Contd..11), H1 2016

Renal Cell Carcinoma - Dormant Projects (Contd..12), H1 2016

Renal Cell Carcinoma - Dormant Projects (Contd..13), H1 2016

Renal Cell Carcinoma - Discontinued Products, H1 2016

Renal Cell Carcinoma - Discontinued Products (Contd..1), H1 2016

Renal Cell Carcinoma - Discontinued Products (Contd..2), H1 2016

Renal Cell Carcinoma - Discontinued Products (Contd..3), H1 2016

List of Figures

Number of Products under Development for Renal Cell Carcinoma, H1 2016

Number of Products under Development for Renal Cell Carcinoma - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Top 10 Routes of Administration, H1 2016

Number of Products by Stage and Top 10 Routes of Administration, H1 2016

Number of Products by Top 10 Molecule Types, H1 2016

Number of Products by Stage and Top 10 Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
AbbVie Inc.
Acceleron Pharma, Inc.
Advenchen Laboratories, LLC
Altor BioScience Corporation
Ambrx, Inc.
Amgen Inc.
Ampio Pharmaceuticals, Inc.
arGEN-X BV
Argos Therapeutics, Inc.
Arrowhead Pharmaceuticals, Inc.
Astellas Pharma Inc.
Bayer AG
Beta Pharma, Inc.
Bio-Cancer Treatment International Limited
BIOCAD
Bionomics Limited
Bionovis SA
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Caladrius Biosciences, Inc.
Calithera Biosciences, Inc.
Cellceutix Corporation
Celldex Therapeutics, Inc.
Celltrion, Inc.
Cerulean Pharma, Inc.
Chipscreen Biosciences Ltd
Cytune Pharma SAS
Dr. Reddy's Laboratories Limited
EirGenix Inc.
Eisai Co., Ltd.
Eli Lilly and Company
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
Genor BioPharma Co., Ltd.
GenSpera, Inc.
GlaxoSmithKline Plc
Horizon Pharma Plc
Hutchison MediPharma Limited
Immatics Biotechnologies GmbH
Immune Design Corp.
Immunicum AB
ImmunoGen, Inc.
Incuron, LLC
Incyte Corporation
KAHR medical Ltd.
Karyopharm Therapeutics, Inc.
KineMed, Inc.
Kyowa Hakko Kirin Co., Ltd.
Lead Discovery Center GmbH
Mabion SA
MacroGenics, Inc.
MediaPharma s.r.l.
MedImmune, LLC
Medivation, Inc.
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
Mirna Therapeutics, Inc.
Molecular Partners AG
Mologen AG
Monopar Therapeutics LLC
Mycenax Biotech Inc.
Nektar Therapeutics
NewLink Genetics Corporation
Novartis AG
NovaTarg Therapeutics, Inc
Omeros Corporation
Oncobiologics, Inc.
OncoMax
Ono Pharmaceutical Co., Ltd.
Panacea Biotec Limited
Peloton Therapeutics, Inc.
Pfizer Inc.
Prima BioMed Ltd.
PsiOxus Therapeutics Limited
Rexahn Pharmaceuticals, Inc.
Seattle Genetics, Inc.
Sevion Therapeutics, Inc.
Sillajen Biotherapeutics
Sorrento Therapeutics, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Syndax Pharmaceuticals, Inc.
Taiwan Liposome Company, Ltd.
TC BioPharm Limited
Theravectys SA
Threshold Pharmaceuticals, Inc.
Tocagen Inc.
TRACON Pharmaceuticals, Inc.
TVAX Biomedical, Inc.
Tyrogenex, Inc.
Vascular Biogenics Ltd.
ViiV Healthcare Limited
X4 Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll